Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The study compared pembrolizumab plus axitinib and sunitinIB for advanced renal cell carcinoma. Median follow-up of 30.6 months showed continued clini...

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

PANORAMA 3 is an open-label, randomized, phase 2 study being done at 71 sites across 21 countries. Patients aged 18 years or older with relapsed or re...

Deep learning model for the prediction of microsatellite instability in colorectal cancer: a diagnostic study

Detecting microsatellite instability (MSI) in colorectal cancer is crucial for clinical decision-making. Universal MSI testing is recommended, but man...

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Combining an agonistic CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumor regression in mice and improves survival. The study w...

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Nadofaragene firadenovec is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium. 55...

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study

Stereotactic ablative body radiotherapy(SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis...

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

A fixed-dose subcutaneous formulation of pertuzumab and trastuzumAB with hyaluronidase was approved by the FDA. The Federica study was designed to ass...

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We did a multicent...

Departments

Recent Posts